The twice-yearly HIV prevention shot just took a big step toward reaching millions more people. On November 2, 2026, India-based Dr. Reddy's Laboratories announced that the U.S. Food and Drug Administration (FDA) has granted tentative approval to its generic version of injectable lenacapavir for HIV pre-exposure prophylaxis (PrEP). It is the first generic version of the shot to clear the FDA, and it is expected to cost US$40 per person per year in 120 low- and middle-income countries. The generic can't be sold in the United States, though. Here's what was approved, why it matters and what it means if you live in the U.S. or are dating across HIV statuses.

What the FDA approved

According to the joint announcement from Unitaid and Dr. Reddy's own press release:

• What it is: A long-acting lenacapavir injection for PrEP, to reduce the risk of sexually acquired HIV-1 in adults and adolescents who weigh at least 77 pounds (35 kg). It is given twice a year.
• Who made it: Dr. Reddy's Laboratories, one of six generic manufacturers that Gilead Sciences, the drug's original maker, licensed in late 2024. Dr. Reddy's received its license in October 2024.
• Under which program: The FDA granted the tentative approval under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) program.
• Price: Under an agreement announced in September 2025 with Unitaid, the Wits Reproductive Health and HIV Institute (Wits RHI) and the Clinton Health Access Initiative (CHAI), the generic will cost US$40 per person per year in the 120 countries covered by Gilead's voluntary license.
• Timing: The first supplies are expected to reach countries before the end of 2026, with broader availability in 2027.
• Speed: Unitaid notes that the generic was approved just 16 months after the FDA approved Gilead's original product for HIV prevention in June 2025. Partners combined lenacapavir's prevention and treatment uses in a single application, which allowed Dr. Reddy's to request and receive a priority review.

What "tentative approval" means

A tentative approval is not a lesser safety review. The FDA explains that it reviews these applications using the same criteria for safety, effectiveness and quality as any other FDA-approved drug. The word "tentative" means the drug meets the requirements for approval but cannot be marketed in the U.S. yet because of patents or exclusivity protecting the original brand-name product.

Tentatively approved HIV medicines can still be bought for use in partner countries through PEPFAR, the Global Fund and similar international programs. AP notes that FDA approval can speed up regulatory approval in many other countries. Dr. Reddy's says the remaining steps toward wider availability include World Health Organization (WHO) prequalification and approvals by national regulators.

Why this matters globally

Until now, Gilead has been the only supplier of lenacapavir, and demand has outstripped supply in low- and middle-income countries, the Associated Press reported. Unitaid says more than 125,000 people in 10 early-adopter African countries have already started Gilead's lenacapavir. We covered that supply gap, including clinics in Uganda rationing doses, in our October report on the global push to reach 3 million people with the twice-yearly PrEP shot.

A US$40 price matters because, according to AP, it is the same price as the daily PrEP pills now available in those countries. A shot every six months means no daily pill to remember, which is one reason advocates see it as a turning point. CHAI's HIV program lead, Carolyn Amole, told AP that an affordable generic could help scale PrEP to the 20 million people worldwide who need it.

Partners were also clear that approval is only one step. "Generic lenacapavir has the potential to transform HIV prevention, and this is a significant milestone, but an affordable drug alone is not enough," said Professor Saiqa Mullick of Wits RHI. Countries still need funding, trained providers, ready health systems and community engagement to turn approval into shots in arms.

What it means if you live in the U.S.

For now, nothing changes at U.S. pharmacies. AP reports that the generic can't be sold in the U.S. because the brand-name version, Yeztugo, is still protected by a patent. The U.S. list price for Yeztugo, before insurance, is $28,218 a year, according to AP.

List price isn't the same as what most people pay. The CDC says most insurance plans and state Medicaid programs cover PrEP, and that under the Affordable Care Act PrEP must be free under almost all health insurance plans, including the medication, clinic visits and lab tests needed to keep your prescription. The CDC also notes that drug companies and some states run assistance programs for people without insurance. PrEP options in the U.S. include daily pills and longer-acting shots, so ask a health care provider or pharmacist which options your plan covers and which one fits your life.

If you're already on lenacapavir PrEP or thinking about it, the basics don't change. The U.S. prescribing information requires a negative HIV test before you start and before each injection, because taking lenacapavir with an undiagnosed HIV infection can lead to drug resistance. AP lists injection site reactions, headache and nausea as common side effects. For what to expect from the shot itself, see our guide to Yeztugo side effects and how long PrEP shot lumps last.

What this means for dating and relationships

For our community, more affordable prevention anywhere is good news, because HIV doesn't stop at borders and stigma shrinks as tools become normal. Closer to home, a few things are worth remembering:

• U=U still comes first in mixed-status couples. A partner with HIV who takes treatment and stays undetectable does not transmit HIV through sex. Read our guide to what U=U means for dating and relationships.
• PrEP is an extra layer for the HIV-negative partner. The CDC lists having a sexual partner with HIV, especially one with an unknown or detectable viral load, among the reasons someone may be a good candidate for PrEP. Our guide to serodiscordant couples covers how partners make these choices together.
• PrEP doesn't prevent other STIs. The CDC notes that PrEP lowers the chance of getting HIV but doesn't protect against other STIs or pregnancy. See how condoms, antivirals and PrEP layer together, and keep up with regular STI testing.
• Prevention is a shared choice, not a demand. Talk openly with partners about what makes each of you feel safe, and respect each other's decisions. If you're meeting someone new, meet in a public place first and take your time.

Quick FAQ

Can I get generic lenacapavir in the U.S.?
No. AP reports that the generic can't be sold in the U.S. while the brand-name version is under patent. The tentative approval allows it to be bought for programs in the 120 countries covered by Gilead's license.

Is the generic as safe and effective as the brand-name shot?
The FDA says it reviews tentative-approval applications using the same safety, effectiveness and quality criteria as any other approved drug. Ask your provider if you have questions about any specific PrEP product.

Does this change PrEP prices for Americans?
Not right now. Most U.S. insurance plans cover PrEP, and the CDC says the Affordable Care Act requires most plans to cover it at no cost to you. Check with your insurer or pharmacist about your own plan.

When will the generic reach people?
Dr. Reddy's and Unitaid expect first supplies in countries before the end of 2026 and broader availability in 2027. Some countries require their own regulatory approval first.

The bottom line

The FDA's tentative approval of the first generic twice-yearly lenacapavir shot is a milestone for HIV prevention worldwide, bringing a US$40-a-year option closer to people in 120 countries where the need is greatest. It doesn't change what's available or what it costs at U.S. pharmacies, and supply, funding and delivery still have to catch up. For people dating with HIV or dating someone who has it, the message stays the same: U=U, PrEP, condoms and regular testing give you more ways than ever to protect each other. If you're looking for people who understand life with HIV, explore HIV dating on MeetPositives.

Sources

• Unitaid. "U.S. FDA approves first generic injectable lenacapavir for HIV prevention." November 2, 2026.
• Dr. Reddy's Laboratories. "U.S. FDA grants tentative approval for Dr. Reddy's twice-yearly injectable lenacapavir, advancing access to HIV prevention across 120 countries outside the US." November 2, 2026.
• Associated Press (Laura Ungar). "Approval of cheap version of HIV-prevention shot raises hopes in low-income countries." November 2, 2026.
• U.S. Food and Drug Administration. "Information for Industry on FDA's Tentative Approval Process Under the PEPFAR Program."
• CDC. "Preventing HIV with PrEP." Updated September 15, 2026.

This article is for general information only and is not medical or legal advice. It does not create a doctor-patient relationship. Talk with a licensed health care provider about your own situation. Laws vary by state; for legal questions, talk with a licensed attorney.